Learning Center
Plans & pricing Sign in
Sign Out
Get this document free

Endpoints-Clinical Trials in Orphan Diseases

 announces, a new market research report is
available in its vast collection:

Endpoints-Clinical Trials in Orphan Diseases - Highest Number of
Terminated Trials Focused on Mulitiple Myeloma


Company, the leading business intelligence provider, has released its
latest research report, “Endpoints-Clinical Trials in Orphan Diseases -
Highest Number of Terminated Trials Focused on Mulitiple Myeloma”
providing an insight into different endpoints that are used in orphan
disease clinical trials. The report examines different aspects of clinical
trial endpoints in orphan diseases, such as analysis of major marketed
orphan drugs with an emphasis on safety and efficacy details, Phase II
and Phase III clinical trial analyses for both completed and ongoing
clinical trials, most promising orphan drugs with more emphasis on safety,
efficacy and clinical trial details, and terminated trial analysis. The
company profiling highlights the orphan drugs of different companies.

These rare diseases have a low rate of prevalence in the existing
population and a physician rarely gets to see patients with these
conditions. Most of the orphan diseases are often genetic and hence they
persist throughout a person’s life. It is estimated that 80% of orphan
diseases have genetic origins. The remaining diseases occur due to
allergies, degenerative and proliferative causes and as a result of infection.
The symptoms for these diseases are not immediate and it appear later for
most of the conditions. The definition of orphan diseases varies with
geography and is primarily dependent upon the prevalence of a disease.


Data and analysis on the marketed products and analysis of their efficacy
and safety details
- Analysis of the seven major orphan diseases which are Huntington’s
disease, acute myeloid leukemia, amyotrophic lateral sclerosis, Hodgkin’s
lymphoma, multiple myeloma, ovarian cancer and pancreatic cancer.

Table of Contents :
1.1 List of Tables 6
1.2 List of Figures 7
2 Endpoints-Clinical Trials in Orphan Diseases - Introduction 8
2.1 Disease Overview 8
2.1.1 The US 8
2.1.2 Europe 8
2.1.3 Japan 8
2.2 Company Report Guidance 8
3 Endpoints-Clinical Trials in Orphan Diseases - Design of Orphan
Diseases Clinical Trials and its Outcomes 9
3.1 Clinical Trial Design - Need For Adaptive Trial Designs In Orphan
Diseases 9
4 Endpoints-Clinical Trials in Orphan Diseases: An Overview on
Endpoints 10
4.1 Types of Clinical Trial Outcomes 10
4.1.1 Oncology Endpoints 10
4.1.2 Other Endpoints 10
5 Endpoints-Clinical Trials in Orphan Diseases - Marketed and Pipeline
Products Assessment 12
5.1 Huntington’s disease 12
5.1.1 Primary Endpoints used in Huntington’s disease Clinical Trials 12
5.1.2 Secondary Endpoints used in Huntington’s disease Clinical Trials 12
5.1.3 Major Marketed Drugs-Safety and Efficacy Analysis 12
5.1.4 Phase III Clinical Trial Analysis 13
5.1.5 Phase III Primary Endpoint analysis 14

For all Related Reports Please follow the link:

More Reports:

Endpoints - Clinical Trials in Cardiovascular Disorders - Optimal Use of
Surrogate Endpoints and Clinical Biomarkers are Key Determinants of

 Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and
Ratings Scales are Becoming More Widely Adopted

 Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints
and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology

For more information kindly visit:

Contact: Marketing Team

Email :


To top